NCT06788509 2026-04-13
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Phase 1 Enrolling by invitation
Clinical Trials
9 trialsNCT07218003 2026-03-23
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Phase 1 Enrolling by invitation
NCT06215846 2025-11-26
A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1 Enrolling by invitation
NCT05423977 2025-09-30
Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1 Enrolling by invitation
NCT06674538 2025-09-22
Clinical Trial to Treat Stage IV Cancer Patients
Moonshot Antibodies
Phase 1 Enrolling by invitation
NCT07053904 2025-07-08
Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors
PharmaEssentia
Phase 1 Enrolling by invitation
NCT06169579 2024-11-15
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
Shenzhen NewDEL Biotech, Co., Ltd
Phase 1 Enrolling by invitation
NCT06616727 2024-09-27
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1 Enrolling by invitation
NCT06205082 2024-03-01
A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor
LittDD Medicines Ltd
Phase 1 Enrolling by invitation